This week’s Edmonds City Council meeting, while short on action items, was taken up with a series of reports providing ...

In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Based on Intelligencia AI’s comprehensive, proprietary database of over 20,000 industry-sponsored, interventional oncology clinical programs (around 12,400 clinical trials), recent insights highlight ...

Thousands of 3D protein structures locked up in big-pharma vaults will be used to create a new AI tool that won’t be open to ...

Drug development programs face unique challenges in demonstrating the safety and effectiveness of drugs for treating rare diseases. The ...

Cell membrane proteins hide secret gateways that can be used to modify cell behavior. This has been demonstrated in a study ...

Clinical trials for drug development are becoming increasingly complex, with numerous variables that must be identified and defined from the start. This complexity arises from rigorous study ...

Investment bankers say large pharma and biotech deals are stalling as executives grapple with mercurial White House economic ...

In the face of such pressure, pharmaceutical companies are eager to reduce the cost of drug development so that consumer prices can be lowered without sacrificing profit margin. Fortunately ...

PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...

Unless government funding materialises to subsidise facilities and staff for a football academy system, FAI director of ...